1395051-45-2Relevant articles and documents
Identification of a potent 5-phenyl-thiazol-2-ylamine-based inhibitor of FLT3 with activity against drug resistance-conferring point mutations
Chen, Chiung-Tong,Hsu, John T.-A.,Lin, Wen-Hsing,Lu, Cheng-Tai,Yen, Shih-Chieh,Hsu, Tsu,Huang, Yu-Ling,Song, Jen-Shin,Chen, Chun-Hwa,Chou, Ling-Hui,Yen, Kuei-Jung,Chen, Ching-Ping,Kuo, Po-Chu,Huang, Chen-Lung,Liu, H.Eugene,Chao, Yu-Sheng,Yeh, Teng-Kuang,Jiaang, Weir-Torn
, p. 151 - 161 (2015)
Abstract Numerous FLT3 inhibitors have been explored as a viable therapy for the treatment of acute myeloid leukemia (AML). However, clinical data have been underwhelming due to incomplete inhibition of FLT3 or the emergence of resistant mutations treated
PYRAZOLE COMPOUNDS AND THIAZOLE COMPOUNDS AS PROTEIN KINASES INHIBITORS
-
Paragraph 0209, (2013/03/26)
A compound of formula (I): wherein A, B, D, X, Y, R1, R2, R3, m, p, and q are defined herein. Also disclosed is a method for inhibiting FMS-like tyrosine kinase 3, aurora kinase, or vascular endothelial growth factor receptor.